



Smart Healthcare: AI's Role in Shaping Personalized Medicine

***Tejal Dingore*, Swati M. Wakchoure¹, Dr. Manisha Nangude², Leena Gharat³**

Student of Shivajirao S. Jondhle College of Pharmacy, Asangaon, Thane, India

¹Assistant Professor Department of Pharmacognosy, ³Assistant Professor Department of Pharmacognosy, ³Student of Shivajirao S. Jondhle College of Pharmacy

Abstract

The application of Artificial Intelligence (AI) in healthcare represents a significant advancement, enhancing our ability to transition from generalized treatment methods to more precise and personalized patient care. Harnessing vast quantities of data from genomics, clinical records, and patient records, AI and (ML) tools provide accurate diagnosis, optimize therapeutic strategy, and improve patient stratifying. Personalized medicine, propelled by advances in gene sequencing, biobanks, pharmacogenomics, and electronic medical records, customizes disease management to each patient's unique genetic and phenotypic profile and shifts health care from reactive to proactive care. Successful applications of AI in healthcare include predictive modelling for disease progression, personalized drug dosing, and drug repurposing. These AI-powered technologies, including predictive analytics, digital twins, robotic surgery, and virtual consultations, help streamline clinical workflows which can ultimately reduce medical errors enhance patient outcomes, and improve cost-effectiveness. Despite the many challenges in data quality, regulatory issues, and clinician-AI collaboration, the transformative potential of AI in personalized medicine underscores AI's ever-growing mission of providing precise, effective, and timely interventions suited to individual patients, hence becoming a principal driver of health care in the future.

Keywords: Artificial Intelligence, Personalized Medicine, Machine Learning, Smart Healthcare, Precision Medicine, Diagnostic Accuracy, Clinical Decision Support

1. Introduction

Personalized medicine diagnoses and treats diseases based on an individual's DNA biographies. Additionally, health markers can be used for gene sequencing and transitioning from post-treatment to treatment. The utility of this technique includes biobanking programs, pharmacogenomics, and electronic health records. Warfarin cure prediction, medicine bracket, and cancer prevention/ treatment are effective operations of machine literacy. The personalized drug aims to deliver the proper intervention to the right case at the right time and cure, which impacts a setback in healthcare performance[1].

1.1. Background and Evolution of Healthcare

In the current decade, efforts toward cost constraints continue. Although health requirements and health services have remained the same, political and social values of the time encourage fiscal constraints. Current values also emphasize state responsibility for maximum health and welfare programs. Recent variations to Medicaid have streamlined the planning and execution processes for countries, providing a clearer frame for program implementation. It's essential to maintain the civil society element of Medicaid backing and ensure that vital services remain available to those who need them. This approach allows for further effective operation while maintaining pivotal support for heirs. Changes have also been implemented in Medicare payment programs to check the added cost, especially for clinical care[2]. The ten times accompaniment featuring huge leaps in AI visibility started attaining greater credence among these health movement professionals. AI provides profound opportunities for designing intelligent products, creating new services, and generating new business models. While adopting AI can improve security, it may also introduce social and ethical challenges concerning privacy, responsibility, and moral rights. AI technologies in medicines live in multitudinous forms, from the purely virtual (e.g., deep-knowledge predicated health information operation systems and active guidance of bears in their treatment opinions) to cyber-physical technologies (e.g., robots used to aid treating surgeons and targeted physicians), nan robots for drug delivery)[3].

Industrial revolutions: A history of invention

Cross-industry deconstruction junctures to frequent aspects of industrialization and democratization. Multitudinous industriousness went through these changeovers in the 19th, 20th, and early 21st centuries. Tremendous value was created, both financially and societally across industriousness. Associations that commanded or quickly embraced these transitions were awarded substantial early imprisonment of that worth. While each maturity path is distinct in its details and cadence, we generally witness diligence progress successively through these five stages of industrialization. Industrialization lifecycle the trends unfolding across diligence reveal several shared characteristics of industrialization: transitions of product and service delivery from craft-based, bottom-up practices to models of assiduity that are increasingly added up, formalized, professionalized, and tech-powered. Most diligence experienced this lifecycle in the 20th century. In the highest felicitations, healthcare release remains early in its artificial journey with all traits most suggestive of foundational and catalyst phases that many other works passed through a century ago[4].

1.2. Introduction to AI in Healthcare

Artificial Intelligence (AI) is revolutionizing healthcare by enhancing individual delicacy, perfecting patient care, streamlining clinical workflows, and enabling personalized drugs. Crucial operations of AI in this field include medical imaging analysis, prophetic analytics, natural language processing, clinical decision support systems, and virtual sidekicks. AI is beneficial to healthcare in improving patient engagement, enhancing data analysis, and reducing medical errors. Challenges persist in the areas of data quality, regulatory frameworks, clinician-AI collaboration, and addressing differences in healthcare. Integrating AI effectively can transform healthcare delivery, enhance outcomes, and lower costs[5]. Artificial Intelligence (AI) revolutionizes medical imaging and diagnostics, enhancing disease detection and reducing errors. Applications include:

- Assessment of ultrasound images for the sight of ischemic heart disease on the Culturomics platform pre-clinical identification of breast and skin cancer, eye diseases, and pneumonia by the imaging body modalities
- Analysing ECG, speech patterns, and neurological disease features
- Machine learning models (ML) for diabetes onset prediction
- clashing COVID-19 through X-ray, CT, ultrasound, and MRI assay[6].

1.3. Machine learning: Neural networks and deep learning

Machine learning is a statistical approach used to fit models to data and 'learn' by training models on data. Machine knowledge is one of the most popularized types of AI; in a 2018 Deloitte check of 1,100 US directors whose associations were formerly exploring AI, 63 of those polled used machine learning in their missions. One of the most familiar uses of classical machine literacy is optimizing conventional medicines. This entails predicting which treatment protocols are expected to succeed based on various patient characteristics and the context of treatment. The maturity of senior machines and the perfect drug transaction provide a training data set with performance variables (e.g. complaints brackets)[7].

2. Why AI in Personalized Medicine is Important:

"Artificial intelligence (AI) is changing personalized medicine, which is tailoring treatments to individual patients," Dr. Nicholas J. Schork writes for 2019. The capacity of AI to analyse complex genomic and phenotypic data, identify patterns and correlations, predict treatment outcomes, optimize treatment strategies, and improve patient stratification and diagnosis makes AI indispensable in Personalized Medicine. By combining multi-dimensional data, forecasting individual reactions, and offering real-time monitoring to modify treatments as needed, AI-driven analytics can effectively categorize cases for therapies, improving their effectiveness. As Schork points out, "AI can help identify complex patterns in data that may not be apparent through other logical approaches" and "can facilitate the development of individualized drugs by identifying subsets of cases that are more likely to respond to specific treatments." AI's ability to reuse vast amounts of data, spot minor trends, provide useful insight, improve therapy efficacy, and address patient concerns makes its application in personalized medicine significant[8].

2.1. The Shifting Healthcare Scene

Artificial Intelligence is dramatically changing healthcare from automating repetition to precision medicine and the practice of prevention. Nowadays, AI identifies patterns in datasets as an application for precision diagnostics. This is what AI will deliver in the next 5 to 10 years: develop powerful algorithms, combine disjointed data, and help precision therapeutics. Long-term, AI-augmented healthcare, and connected care will shift medicine from one-size-fits-all to personalized, data-driven disease management, improving patient outcomes, experiences, and cost-effectiveness. AI-powered remote monitoring, intelligent telehealth, and interoperable digital infrastructure will connect healthcare stakeholders, revolutionizing the industry[9].

2.2. AI is revolutionizing healthcare in four areas. First, the use of Digital Twins with artificial intelligence:

The possibility of testing new drugs and treatments on virtual models of humans or specific organs opens avenues for far fewer false negatives and positives. Second, AI-Powered Robotic Surgery: Advances in remote surgeries can lead to autonomous robots performing tasks like ultrasound imaging, thus saving physicians time and resources. Virtual care consultations use AI to analyse patient symptoms, generate treatment options, and clarify insurance coverage, enhancing focused care and improving outcomes. AI predictive capabilities can identify life-threatening diseases that kill millions of patients each year, including acute kidney injury (AKI), providing an early intervention and prevention solution. These innovations demonstrate the potential for transformation in healthcare by AI by improving the quality of patient care, smoothing clinical workflows, and supporting the conduction of medical research¹⁰. Four key concerns may cause healthcare professionals, especially physicians, to resist a more widespread adoption of augmented medicine. Many individuals lack basic and ongoing education in digital medicine, which hinders their understanding of its potential. Early digitization efforts have made the management of life administration more burdensome, contributing to the current issue of physician burnout. There is a concern about AI supplanting doctors, although the literature indicates that AI will complement rather than supplant

human mindsets. Finally, the legal grey area on algorithm liability places a risk on physicians. To overcome some of these challenges, some medical faculties increase their understanding of engineering and digital health in their curricula and demonstrate future managers for an era of augmented medicine[11].

3. Healthcare Reforms and Cost Constraints


Medicare and Medicaid payments would be regulated under health reform law: Medicare and Medicaid payments would be reduced under changes intended to provide the nation with \$416 billion in cost savings between 2010 and 2019, as estimated by the CBO. This cut offsets the added medical expense of insuring the previously uninsured, leaving a net reduction in spending of \$1 billion over the same period. This estimation is in line with the OACT's estimated increase of \$311 billion in national medical spending. This estimation is based on the assumptions that underlie this estimation: no price increase for private payers and no cost-shifting that arises from decreasing uninsured patients, following empirical evidence and other estimators' practices[16].

Proper diffusion of technology within healthcare is cost-effective. Technologies must be adopted if they reduce the cost per unit with better outcomes than current ones do. Cost-effectiveness analysis has been widely used to guide resource allocation. However, applying this principle is challenging due to limited data on effectiveness and costs. Examples show that technologies can be cost-effective in specific clinical situations but not others. The U.S. healthcare system's economic incentives have changed, from cost-based reimbursement to prospective payment systems and managed care, which encourage cost-consciousness without ensuring the adoption of cost-effective technologies. The three principal stakeholders—hospitals, managed care plans, and physicians—possess distinct incentives. Therefore, decisions concerning the adoption of technology and the allocation of resources must be approached with careful consideration[17].

Healthcare reforms aim to ameliorate effectiveness amidst rising costs. Cost-effectiveness analysis(CEA) helps allocate coffers effectively. Crucial considerations:

- Input constraints(e.g., limited coffers, capacity)
- Resource allocation decision rules
- Negotiating Individual Case Needs with Societal Budgetary Constraints

Effective CEA informs opinions with the optimization of healthcare benefits within limited budgets[18].



Sustainable systems, innovative technologies, and artificial intelligence will facilitate development progress. AI-driven outcomes include:

Simplify the process for scheduling appointments and managing prescriptions.

Enable effective remote connectivity.

Promote effective information sharing.

Improved patient satisfaction and outcomes.

AI and connected care systems make care delivery efficient, productive, and patient-centred, while healthcare becomes sustainable.

Figure 2. Employing AI for Personalize Medicine [19,20,21]

3.1. Precision Medicine through Health IT

- Electronic health records (EHR), when combined with genomics data, enhance the development of perfect drugs.
- Megahit provides the installation for data-driven approaches to individualized drugs.
- AI and ML dissect large datasets to serve the perceptivity of the perfect drug.

3.2. AI Applications in Precision Medicine:

- Predictive analytics for disease risk and treatment response.
- Genomic analysis for targeted therapies. Natural Language Processing (NLP) for phenotype extraction. Profound literacy for match analysis and opinion [22,23,24,25]

3.3. Personalized Medicine in Action:

The goal of individualized pharmacotherapy has been on the agenda of healthcare providers for decades, and one of the key elements in this effort has been the principles of rational use of drugs or rational pharmacotherapy. The essence of these principles was that individual cases should allow for specific considerations relevant to their clinical needs to maximize benefits and reduce harm. Formerly in the 1960s and 70s, these principles were restated into, for illustration, "the right medicine for the right case in the right cure at the right time" [26,27,28].

For decades, we have witnessed significant advancements in molecular medicine, enabling us to gradually pursue more individualized pharmacotherapy and develop drugs tailored for specific patient subgroups. We have gained a deeper molecular understanding of the drug's mechanism of action and the exposure-response relationship. We further realized that most diseases are heterogeneous and drugs should be designed to achieve more effective and safer pharmacotherapy [29,30,31].


4. The Lifecycle of AI in Personalized Medicine

Generative AI Changes Perfected Medicine Generates humongous chunks of medical information to make available treatments based on someone's particular profile of being heritable life and terrain. Advantages Create new prototypes of drugs Predicted side effects by optimizing drugs' efficacy Suggest potential treatment plans Earlier discovery of complaints Much richer analysis in medical images[31].

Generative AI Changes Perfected Medicine Generates humongous gobbets of medical information to make available treatments grounded on someone's particular profile of being inheritable life and terrain. Advantages produce new prototypes of medicines prognosticated side goods by optimizing medicines efficacy Suggest implicit treatment plans. The earlier identification of complaints is essential for a more comprehensive analysis of medical images[33].

5. Evolution of Healthcare with Artificial Intelligence: Opportunities and Outcomes

This revolution in health care with Artificial Intelligence (AI) has significantly opened up tremendous scope for betterment in this sector with promising outcomes. Below are comprehensive developments regarding the evolution of AI in healthcare, including relevant data and reference [35]






Figure 4. Openings [36,37,38]

5.1. Outcomes:

- Reduced Diagnostic Errors: AI-assisted diagnosis reduced errors by 20-30% in some studies[39].
- Improved Patient Engagement: AI-powered chatbots and virtual assistants increased patient engagement by 25-50%[40].
- Enhanced Clinical Decision Support: AI-driven clinical decision support systems improved adherence to guidelines by 20-40%[41].
- Reduced Healthcare Costs: AI-driven efficiency and automation saved an estimated \$150 billion in US healthcare costs in 2020[42].
- Improved Patient Outcomes: AI-assisted care resulted in reduced hospital readmissions (10-20%), fewer complications (5-15%), and improved patient satisfaction (10-20%)[43].

5.2. Key Statistics:

- 81% of healthcare executives believe AI will revolutionize healthcare by 2025[44].
- 71% of healthcare organizations are investing in AI, with 45% already using AI in some capacity[45].
- The across-the-board AI in healthcare requests is projected to reach \$150 billion by 2027, raising at a CAGR of 41.8[46].

Conclusion

The integration of Artificial Intelligence is sweeping into the healthcare industry to transform its course. AI-driven analytics and machine learning algorithms can analyse vast genomic, phenotypic, and clinical data to effectively predict disease risk, optimize treatment plans, and improve individual patient outcomes. By implementing AI, healthcare organizations can significantly improve patient engagement, optimize clinical workflows, reduce operational costs, and enhance the quality of care provided. The applications of AI in healthcare vary widely, including predictive analytics, medical imaging analysis, natural language

processing, clinical decision support systems, and virtual assistants. Successful implementations have shown significant reductions in individual errors (20-30%), improved patient satisfaction (10-20%), and declining healthcare costs, which are expected to reach \$150 billion in 2020. Artificial intelligence (AI) has the potential to fundamentally transform healthcare delivery, enhance health outcomes, and reduce costs. A noteworthy 81 percent of healthcare executives believe that AI will significantly revolutionize the industry by 2025, indicating considerable promise for advancements in personalized medicine. However, many challenges remain to be addressed, including obtaining quality data, establishing appropriate regulatory frameworks, fostering collaboration between doctors and AI experts, and addressing healthcare inequalities.

Reference:

1. Gifari M.W., Samodro P., Kurniawan D.W., "Artificial Intelligence Toward Personalized Medicine," *Pharmaceutical Sciences and Research*, 2021, 8 (2), 65–72. <https://www.pharmacologyeducation.org/>
2. Frieden T.R., "The Future of Public Health," *New England Journal of Medicine*, 2015, 373 (18), 1748–1754. <https://doi.org/10.1056/NEJMs1511248>
3. Johnson K.B., Wei W.Q., Weeraratne D., Frisse M.E., Misulis K., Rhee K., Zhao J., Snowdon J.L., "Precision Medicine, AI, and the Future of Personalized Health Care," *Clin Transl Sci*, 2021, 14 (1), 86–93. doi: 10.1111/cts.12884
4. Almohareb S.N., Aldairem A., Alrashed M., Bin Saleh K., Badreldin H.A., Al Yami M.S., Al Harbi S., Albekairy A.M., "Revolutionizing Healthcare: The Role of Artificial Intelligence in Clinical Practice," *BMC Medical Education*, 2023, 23 (1), 689. <https://doi.org/10.1186/s12909-023-03992-x>
5. Al Kuwaiti A., Nazer K., Al-Reedy A., Al-Shehri S., Al-Muhanna A., Subbarayalu A.V., Al Muhanna D., Al-Muhanna F.A., "A Review of the Role of Artificial Intelligence in Healthcare," *J Pers Med*, 2023, 13 (6), 951. doi: 10.3390/jpm13060951
6. Davenport T., Kalakota R., "The Potential for Artificial Intelligence in Healthcare," *Future Healthc J*, 2019, 6 (2), 94–98. doi: 10.7861/futurehosp.6-2-94
7. Habehh H., Gohel S., "Machine Learning in Healthcare," *Current Genomics*, 2021, 22 (4), 291–300. <https://doi.org/10.2174/1389202922666210705124359>
8. Goetz L.H., Schork N.J., "Personalized Medicine: Motivation, Challenges, and Progress," *Fertility and Sterility*, 2018, 109 (6), 911–919. <https://doi.org/10.1016/j.fertnstert.2018.05.006>
9. Bajwa J., Munir A.U., Nori A., Williams B., "Artificial Intelligence in Healthcare: Transforming the Practice of Medicine," *Future Healthc J*, 2021, 8 (2), e188–e194. <https://doi.org/10.7861/fhj.2021-0095>
10. Puaschunder J.M., "The Future of Artificial Intelligence in International Healthcare: An Index," *Scientia Moralitas Research Institute*. Retrieved from <http://dx.doi.org/10.2139/ssrn.3623530>
11. Briganti G., Le Moine O., "Artificial Intelligence in Medicine: Today and Tomorrow," *Frontiers in Medicine*, 2020, 7, 27. <https://doi.org/10.3389/fmed.2020.00027>
12. Van Baal P., Morton A., Severens J.L., "Healthcare Input Constraints and Cost-effectiveness Analysis Decision Rules," *Social Science & Medicine*, 2018, 200, 59–64. <https://doi.org/10.1016/j.socscimed.2018.01.026>
13. World Health Organization (WHO), "18th Meeting of Ministers of Health, Kathmandu, Nepal, 23–25 August 2000: Health Sector Reform: Issues and Opportunities," 2000.
14. World Health Organization, "Global Report on Health Equity for Persons with Disabilities," 2022.

15. World Health Organization, "WHO Global Report on Traditional and Complementary Medicine 2019," 2019.
16. Neelsen S., Limwattananon S., O'Donnell O., van Doorslaer E., "Universal Health Coverage: A (Social Insurance) Job Half Done?" *World Development*, 2019, 113, 246–258. <https://doi.org/10.1016/j.worlddev.2018.09.004>
17. Cutler D.M., Davis K., Stremikis K., "The Impact of Health Reform on Health System Spending," *Issue Brief (Commonw Fund)*, 2010, 88, 1–14. PMID: 20491172
18. Institute of Medicine (US) Committee on Technological Innovation in Medicine; Gelijns A.C., Halm E.A., editors, "The Changing Economics of Medical Technology," National Academies Press (US), Washington (DC), 1991. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK234309/>
19. Yu J., Liu Z., Zhang T., et al., "Measuring Productivity of Healthcare Services Under Environmental Constraints: Evidence from China," *BMC Health Serv Res*, 2020, 20, 673. <https://doi.org/10.1186/s12913-020-05496-9>
20. Siemens Healthineers, "Insights Series Transforming the System of Care Perspectives," Issue 49. Retrieved from <https://www.siemens-healthineers.com/transforming-the-system-of-care>
21. Wyns A., Bragge P., Armstrong F., Carino S., Dolker D., Lennox A., Tsering D., "A Review of Sustainable Healthcare Policy, Practice, and Research with a Focus on Safety and Quality," ACSQHC, Sydney, 2022.
22. Hameed F., Hameed K., "The Role of Digital Transformation in Healthcare: A Sustainability Perspective, Design and Integration Challenges, Security and Privacy Challenges, Blockchain Technology, Applications, Future Research Directions," *Preprints*, 2023. <https://doi.org/10.20944/preprints202308.0867.v1>
23. Zayas-Cabán T., Chaney K.J., Rogers C.C., Denny J.C., White P.J., "Meeting the challenge: Health information technology's essential role in achieving precision medicine," *Journal of the American Medical Informatics Association*, 2021, 28 (6), 1345–1352.
24. Jen M.Y., Kerndt C.C., Korvek S.J., "Health Information Technology," In: *StatPearls* [Internet], Treasure Island (FL): StatPearls Publishing, 2024 Jan–, 2023 Jun 20. PMID: 29262233.
25. Kaplan B., "Revisiting health information technology ethical, legal, and social issues and evaluation: Telehealth/telemedicine and COVID-19," *International Journal of Medical Informatics*, 2020, 143, 104239. <https://doi.org/10.1016/j.ijmedinf.2020.104239>
26. Alotaibi Y.K., Federico F., "The impact of health information technology on patient safety," *Saudi Medical Journal*, 2017 Dec, 38 (12), 1173–1180. doi: 10.15537/smj.2017.12.20631. PMID: 29209664; PMCID: PMC5787626.
27. Jørgensen J.T., "Twenty years with personalized medicine: Past, present, and future of individualized pharmacotherapy," *Oncologist*, 2019 Jul, 24 (7), e432–e440. doi: 10.1634/theoncologist.2019-0054. Epub 2019 Apr 2. PMID: 30940745; PMCID: PMC6656435.
28. Klett C.J., Moseley E.C., "The right drug for the right patient," *Journal of Consulting Psychology*, 1965 Dec, 29 (6), 546–551. doi: 10.1037/h0022770. PMID: 5846125.
29. Galbrecht C.R., Klett C.J., "Predicting response to phenothiazines: The right drug for the right patient," *Journal of Nervous and Mental Disease*, 1968 Aug, 147 (2), 173–183. doi: 10.1097/00005053-196808000-00009. PMID: 5677325.
30. Lesko L.J., Schmidt S., "Individualization of drug therapy: History, present state, and opportunities for the future," *Clinical Pharmacology & Therapeutics*, 2012 Oct, 92 (4), 458–466. doi: 10.1038/clpt.2012.113. Epub 2012 Sep 5. PMID: 22948891.

31. Jørgensen J.T., “A challenging drug development process in the era of personalized medicine,” *Drug Discovery Today*, 2011, 16 (19–20), 891–897. <https://doi.org/10.1016/j.drudis.2011.09.010>
32. Piplani Y., Mehra P.S., “An unsupervised learning model for Ayurvedic Prakriti determination using smart device data,” 2024 OPJU International Technology Conference (OTCON) on Smart Computing for Innovation and Advancement in Industry 4.0, Raigarh, India, 2024, 1–6. doi: 10.1109/OTCON60325.2024.10688039
33. Taherdoost H., Ghofrani A., “AI's role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy,” *Intelligent Pharmacy*, 2024, 2 (5), 643–650. <https://doi.org/10.1016/j.ipha.2024.08.005>
34. R P., “AI revolutionizes precision medicine: Benefits, case study & future trends,” *intuz.com*, 2024 Jun 17 [Updated July 18, 2024]. Retrieved from <https://www.intuz.com/blog/generative-ai-in-precision-medicine>
35. Chung W.K., Erion K., Florez J.C., et al., “Precision medicine in diabetes: A consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” *Diabetes Care*, 2020 Jul, 43 (7), 1617–1635. <https://doi.org/10.2337/dci20-0022>
36. Li R., Niu Y., Scott S.R., Zhou C., Lan L., Liang Z., Li J., “Using electronic medical record data for research in a Healthcare Information and Management Systems Society (HIMSS) Analytics Electronic Medical Record Adoption Model (EMRAM) Stage 7 hospital in Beijing: Cross-sectional study,” *Journal of Medical Internet Research*, 2021, 9 (8), e24405. doi: 10.2196/24405
37. Van Calster B., Wynants L., Timmerman D., Steyerberg E.W., Collins G.S., “Predictive analytics in health care: How can we know it works?” *Journal of the American Medical Informatics Association*, 2019, 26 (12), 1651–1654. <https://doi.org/10.1093/jamia/ocz130>
38. Hyder M.A., Razzak J., “Telemedicine in the United States: An introduction for students and residents,” *Journal of Medical Internet Research*, 2020, 22 (11), e20839. doi: 10.2196/20839
39. Schiff G.D., Hasan O., Kim S., et al., “Diagnostic error in medicine: Analysis of 583 physician-reported errors,” *Archives of Internal Medicine*, 2009, 169 (20), 1881–1887. doi: 10.1001/archinternmed.2009.333
40. Lai Y., Lioliou E., Panagiotopoulos P., “Understanding users’ switching intention to AI-powered healthcare chatbots,” *ECIS 2021 Research Papers*, 2021, 51. https://aisel.aisnet.org/ecis2021_rp/51
41. Pawloski P.A., Brooks G.A., Nielsen M.E., Olson-Bullis B.A., “A systematic review of clinical decision support systems for clinical oncology practice,” *Journal of the National Cancer Institute*, 2019, 17 (4), [Online]. <https://doi.org/10.6004/jnccn.2018.7104>
42. Banerjee A., Chakraborty C., Kumar A., Biswas D., “Emerging trends in IoT and big data analytics for biomedical and healthcare technologies,” In: *Handbook of Data Science Approaches for Biomedical Engineering*, 2020, 121–152. <https://doi.org/10.1016/B978-0-12-818318-2.00005-2>
43. MacGillivray T.E., “Advancing the culture of patient safety and quality improvement,” *Methodist DeBakey Cardiovascular Journal*, 2020, 16 (3), 192–198. <https://doi.org/10.14797/mdcj-16-3-192>
44. Przytuła S., Strzelec G., Krysińska-Kościńska K., “Re-vision of future trends in human resource management (HRM) after COVID-19,” *Journal of Intercultural Management*, 2020, 12 (4), 70–90. <https://doi.org/10.2478/joim-2020-0052>
45. Furukawa M.M., Pollack E., “Achieving HIMSS Stage 7 designation for EMR adoption,” *Nursing Management* (Springhouse), 2020, 51 (1), 10–12. <https://doi.org/10.1097/01.NUMA.0000617044.57943.e1>
46. Mrazek M., O'Neill F., “Artificial intelligence and healthcare in emerging markets,” *International Finance Corporation [IFC]*, (n.d.). Retrieved from <https://www.ifc.org/en/home>